Ardea hasinitiated Taylor Swift a multiple ascending dose MAD

Ardea hasinitiated studies taylor swifts a multiple taylor jr imparts ascending dose (MAD) study of RDEA594 in healthy volunteersto investigate the safety, pharmacokinetics, and pharmacodynamics of RDEA594administered once daily for 10 days. "The results from the SAD study demonstrate the tolerability and potent activityof RDEA594 in reducing serum uric acid," commented Barry D Quart, PharmD,president and chief executive officer. "We have continued our expediteddevelopment of this compound with the initiation late last year of the MADstudy, which is designed to identify doses for the planned Phase 2 dose-responsestudy in gout patients later this year." About RDEA594RDEA594 is a major metabolite of RDEA806, our lead non-nucleoside reversetranscriptase inhibitor (NNRTI) in clinical development for the treatment ofpatients with human immunodeficiency virus (HIV). RDEA594 does not haveantiviral activity and is responsible for the uric acid-lowering effectsobserved following administration of RDEA806 to over 150 subjects in Phase 1 andPhase 2 clinical trials. RDEA594 is believed to be an inhibitor of the URAT1transporter in the kidney, which is responsible for the regulation of uric acidlevels.

About Ardea Biosciences, Inc.Ardea Biosciences, Inc., of San Diego, California, is a biotechnology companyfocused on the discovery and development of small-molecule therapeutics for thetreatment of HIV, gout, cancer and inflammatory diseases taylor swifts brother . We have five productcandidates in clinical trials and others in preclinical development anddiscovery taylor residential . Our most advanced product candidate is RDEA806, an NNRTI, which hassuccessfully completed a Phase 2a study for the treatment of patients with HIV.We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427,in a human micro-dose pharmacokinetic study and have selected it for clinicaldevelopment based on a plasma half-life of greater than 40 hours taylor road . RDEA594, ourlead product candidate for the treatment of hyperuricemia and gout, is beingevaluated in Phase 1 clinical trials taylor mary . We are evaluating our lead MEK inhibitor,RDEA119, in a Phase 1/2 study in combination with sorafenib (Nexavar®, OnyxPharmaceuticals, Bayer HealthCare) and as a single agent in a Phase 1 study,both in advanced cancer patients, and have completed a Phase 1 study in normalhealthy volunteers as a precursor to trials in patients with inflammatorydiseases. Lastly, we have evaluated our second-generation MEK inhibitor for thetreatment of cancer and inflammatory diseases, RDEA436, in a human micro-dosepharmacokinetic study and have selected it for clinical development. Statements contained in this press release regarding matters that are nothistorical facts are "forward-looking statements" within the meaning of thePrivate Securities Litigation Reform Act of 1995.Because such statements aresubject to risks and uncertainties, actual results may differ materially fromthose expressed or implied by such forward-looking statements.Such statementsinclude, but are not limited to, statements regarding our plans and goals, theexpected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436and our other compounds and the timing and results of our preclinical, clinicaland other studies and our financial performance.Risks that contribute to theuncertain nature of the forward-looking statements include risks related to theoutcome of preclinical and clinical studies, risks related to regulatoryapprovals, delays in commencement of preclinical and clinical studies, costsassociated with our drug discovery and development programs, and risks relatedto the outcome of our business development activities.These and other risks anduncertainties are described more fully in our most recently filed SEC documents,including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q,under the headings "Risk Factors."All forward-looking statements contained inthis press release speak only as of the date on which they were made.Weundertake no obligation to update such statements to reflect events that occuror circumstances that exist after the date on which they were made.Ardea Biosciences, Inc.John Beck, Copyright Business Wire 2009.

Patented Software Replacing Anti-Virus on More Than 100,000 DevicesCUPERTINO, Calif.--(Business Wire)--Solidcore Systems, Inc., a leader in protecting critical IT infrastructure,today announced that the United States Patent and Trademark Office has grantedthe company U.S taylor swifts fearless . patent number 7,464,408 titled "Damage Containment byTranslation." This is a foundational patent that covers Solidcore'ssingle-solution for securing endpoints like point-of-sale (POS) systems, ATMs,Kiosks, and virtual environments where anti-virus technology does not work.Solidcore's patented technology replaces anti-virus by preventing known andunknown computer threats, security risks, and malicious code with zeroperformance overhead taylor artist . Solidcore's patented endpoint security technology is the first to combinedynamic whitelisting, host intrusion prevention and file integrity monitoringcapabilities taylor sarah . The technology is the foundation for Solidcore's S3 Control, POSCheck & Control, and S3 Control Embedded products, and is currently replacinganti-virus on more than 100,000 endpoints worldwide taylor thomas . The patented technologyensures only pre-authorized software and code can run on a computer system whilesecurely allowing software updates from trusted sources. Solidcore prevents disktampering and provides advanced memory protection to authorized software todefend against buffer overflow vulnerability attacks and zero-day exploits. Thislevel of protection extends across all forms of computer access, includingaccess from a network or a USB key.

Solidcore's single-solution for endpointsecurity also shortens the time, simplifies the effort, and lowers the costs formeeting Payment Card Industry (PCI) compliance across store systems . "This patent is a significant advancement for securing fixed-function devicesand virtualized environments, which are two critical IT segments whereanti-virus and the blacklisting security model simply does not work," said RosenSharma, chief technology officer for Solidcore taylor countrywide . "The patent reinforces Solidcoreas the leader for providing comprehensive security and PCI compliance acrossfixed-function devices, and it represents the foundation for how users willsecure virtualized environments." Solidcore's patented technology is providing security and PCI compliance forcritical systems throughout the world, and is the chosen protection solution formany of the world's leading fixed-function device manufacturers, including NECInfrontia point-of-sale systems, NCR automated teller machines (ATMs), and Sharpmultifunction printers taylor mt . The patented technology, which powers the Solidcore S3Control Embedded software platform, was also recently awarded "NSS LabsApproved" by NSS Labs, the globally recognized leader in independent securitytesting and certification . About SolidcoreSolidcore is a leader in protecting critical IT infrastructure from devices tothe data center.